Squamous-cell carcinoma of the lung

The Worldwide Non-Small Cell Lung Cancer Treatment Industry is Expected to Reach $25.7 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022

The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC).

Key Points: 
  • The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC).
  • As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.
  • Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic.
  • The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries.

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

Retrieved on: 
Tuesday, April 13, 2021

In China, specifically, the approved options for second-line immunotherapy to treat squamous non-small cell lung cancer are even more limited.

Key Points: 
  • In China, specifically, the approved options for second-line immunotherapy to treat squamous non-small cell lung cancer are even more limited.
  • We hope that the positive results of ORIENT-3 can help more squamous non-small cell lung cancerpatients.
  • "In August 2020, the NMPA accepted a new indication application for TYVYT (sintilimab injection) in combination with chemotherapy for first-line treatment of squamous NSCLC.
  • We look forward to working together to potentially bring this new treatment option to people in China with squamous non-small cell lung cancer.

New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions

Retrieved on: 
Tuesday, May 19, 2020

The article titled, Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma, was published in the peer-reviewed journal, Current Medical Research and Opinion (CMRO).

Key Points: 
  • The article titled, Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma, was published in the peer-reviewed journal, Current Medical Research and Opinion (CMRO).
  • Results of the study demonstrate that integration of DecisionDx-SCC (40-gene expression profile test) results impacted management decisions in a significant and risk-appropriate manner for high-risk SCC patient scenarios, while remaining aligned with national guidelines for patient management.
  • These results demonstrate that information on tumor biology can impact clinical decisions in a significant, risk-appropriate manner.
  • They were then asked to rate clinicopathological features and DecisionDx-SCC test results to assess their opinion of how concerning each is to SCC prognosis.